Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma

Presented by:
Natalie S. Callander
Search for other papers by Natalie S. Callander in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 19: Issue 11.5
Online Publication Date:
Nov 2021
DOI:
https://doi.org/10.6004/jnccn.2021.5105
Restricted access

Numerous treatment options are available for patients with early relapsed multiple myeloma. Clinicians should consider using a monoclonal antibody for patients who have not yet received one, or changing either the immunomodulatory drug, the proteasome inhibitor, or both. Clinical trials are another option, or clinicians can refer transplant-naïve patients for autologous stem cell transplantation (ASCT). For patients with late relapse, a clinical trial is recommended, if possible, but many patients are ineligible due to poor blood cell counts or other factors. Additional treatment options include selinexor combinations, belantamab mafodotin-blmf, melflufen, or CAR T-cell therapy. Salvage ASCT should also be considered for this challenging population.

Disclosures: Dr. Callander has disclosed having no relevant financial relationships.

Correspondence: Natalie S. Callander, MD, University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, WIMR 4059, Madison, WI 53792. Email: nsc@medicine.wisc.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Kumar SK, Callander NS, Adekola K, et al. NCCN Clinical Practice Guidelines on Oncoloy for Multiple Myeloma. Version 1.2022. Accessed September 20, 2021. To view the most recent version, visit NCCN.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22:801–812.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet 2020;396:186–197.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Moreau P, Dimopoulos MA, Yong K, et al. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA phase III study design. Future Oncol 2020;16:4347–4358.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 2018;379:1811–1822.

  • 6.

    Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med 2019;381: 727–738.

  • 7.

    Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 2020;21:207–221.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Richardson PG, Oriol A, Larocca A, et al. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol 2021;39:757–767.

  • 9.

    Jagannath S, Lin Y, Goldschmidt H, et al. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J 2021;11:116.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2021 by the National Comprehensive Cancer Network 2021
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
Nov 2021
Online Publication Date:
Nov 2021

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1520 269 71
PDF Downloads 487 47 8
EPUB Downloads 0 0 0